1 / 20

Fever and febrile seizures in NZ children following 2010 trivalent inactivated influenza vaccines

Fever and febrile seizures in NZ children following 2010 trivalent inactivated influenza vaccines. Helen Petousis-Harris, Nikki Turner , Tracey Poole, Department of General Practice and Primary Health Care Immunisation Advisory Centre University of A uckland.

manjit
Download Presentation

Fever and febrile seizures in NZ children following 2010 trivalent inactivated influenza vaccines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fever and febrile seizures in NZ children following 2010 trivalent inactivated influenza vaccines Helen Petousis-Harris, Nikki Turner, Tracey Poole, Department of General Practice and Primary Health Care Immunisation Advisory Centre University of Auckland Co-investigators: Robert Booy, Gary Reynolds

  2. Background • April 2010 Western Australia detected increase in spontaneous reporting of febrile convulsions, single brand? • Estimated 1/110 within 4-6 hours in ≤ 5 year olds • April 2010 NZ no signals from CARM • 24th April total of 4 reports • Rapid analysis of ED and admission data for Ak region children hospitals (1.5 million) • No more FC than normally expected (~25 each per week)

  3. Actions taken Australia April 23rd New Zealand April 26th Recommendation not to give Fluvax brand to under 5s as precaution Stocks of Fluvax exhausted anyway • Influenza programme for children under five years suspended • Insufficient data on other brands to support their continued use Collaboration between Australian NCIRS, sanofipasteur and IMAC

  4. Research • NZ in unique position to evaluate the safety of several brands of flu vaccine in young children • TIVs used for 2010: Vaxigrip, Fluvax, Influvac • All A/California/7/2009(H1N1),A/Perth/16/2009 (H3N2), B/Brisbane/60/2008 • (also one monovalent A/California/7/2009(H1N1): Celvapan) OBJECTIVES 1. Assess rate of febrile reactions following Vaxigrip and Fluvax in ≤ 5 years 2. Assess rate of febrile convulsion following Vaxigrip and Fluvax in ≤ 5 years 3. Assess reactogenicity of these vaccines in other age groups

  5. Methodology • Primary care practices (practice nurses) identify consecutive vaccinees and run telephone questionnaire • Administer brief 6 (7) item survey • Vaccine identified by batch number • Three 2010 studies (total of 4142 doses) • 473 x 18 – 55 years (IMAC) • 100 x 6 years – 18 years (CSL) • 3569 x 6mos – 5 years (Sanofi)1 1. Petousis-Harris H, Poole T, Booy R, Turner N. Fever following administration of two inactivated influenza vaccines – A survey of parents of New Zealand infants and children 5 years and under. Vaccine.(2011) 29: 2933-2937.

  6. Definitions • Fever either reported or measured • If measured then defined as ≥38°C • further defined into ≥38°C, ≥39°C and ≥40°C. • Major Febrile Events • Fever + ED/hospital visit • Fever + GI symptoms (vomiting) • Fever + musculoskeletal symptoms • Fever and malaise/lethargy • Fever and neurological symptoms • Rigors • Altered consciousness • Convulsive seizure • Defined as per Brighton Collaboration definitions Bonhoeffer J. Fever as an Adverse Event following Immunisation Case Definition and Guidelines of Data Collection, analysis and Presentation. Vaccine 2003:1 -6. Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004;22(5-6):557-62.

  7. Verification of cases • Clinical records obtained and/or further information sought via clinician interview for following: • Sought medical attention • Reported any neurological symptoms

  8. Recall bias • Ability of parents to recall events as time between vaccination and survey increased • Logistic regression • Outcome • fever recalled within 24 hours or not • Explanatory variables • Lag time from vaccination to survey • Vaccine • Age and age squared in months • Summer/winter (May-Oct, Nov-Apr)

  9. Results for infants and children

  10. Results - recruitment There were 3188 children and 2244 parents/caregivers in our sample providing data for 3569 doses of vaccine. There was an average of 1.1 doses given per child.

  11. Characteristics of vaccinees

  12. Major febrile events occurring in Vaxigrip® and Fluvax® recipients *Witnessed loss of consciousness and tonic/clonic seizure.

  13. Comparison of febrile events in children ≤5 years following 3559 doses of 2010 flu vaccine Celvapan, 10 doses, 2 medical advice, one fever and vomiting and one fever. 3 fevers within 24 hours

  14. Other age groups and 2011 data

  15. 6 - 9 years

  16. Youth aged 10 – 17 years • Active surveillance (post vaccine diary) • 69 diaries post Fluvax. 1/69 fever of 38.2°C

  17. Adults aged 18 – 70 years • Active surveillance (post vaccine diary) • 156 diaries. No fevers • Local reactions

  18. Ethnicity a risk for feverChildren 6/12 – under 6 years N=329 Male/Female 19%/26%

  19. Conclusions • Febrile convulsions high following a single brand of flu vaccine 13-38 per 10,000 doses Cf with: wDTP vaccine 6-9 per 100,000 MMR 25-34 per 100,000 • UK enhanced passive surveillance found 2/10,000 and 1.4/10,000 following H1N1 • No excess in reporting • Not all brands/years equivalent • Further attention and resources to support programme design and planning and to maintain public confidence.

  20. Thank you

More Related